---
title: "Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Humanistic burden and health-related quality of life"
description: "Formulary evidence on Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Humanistic burden and health-related quality of life. Topics: SF-36 component scores, anxiety, and depression in 136 US adults with physician-diagnosed NASH versus matched general population and type 2 diabetes cohorts, 2016 National Health and Wellness Survey; SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network; Physical health-related patient-reported outcomes in 72 adults with biopsy-proven NASH and F2 or F3 fibrosis, as summarized in a systematic review; Patient-reported outcomes in 1667 adults with NASH and F3 or F4 fibrosis versus the general population, STELLAR trial baseline; 11 further topics. 15 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description/humanistic-burden-and-health-related-quality-of-life"
published: "2026-11-18T22:34:49-05:00"
modified: "2026-11-18T22:34:49-05:00"
---

# Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Humanistic burden and health-related quality of life

<a id="heading-2.2.1.8.1"></a>

## 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

### SF-36 component scores, anxiety, and depression in 136 US adults with physician-diagnosed NASH versus matched general population and type 2 diabetes cohorts, 2016 National Health and Wellness Survey

> “Data came from the 2016 National Health and Wellness Survey, a nationally representative patient-reported outcomes survey conducted in the United States. Respondents with physician-diagnosed NASH, physician-diagnosed T2DM, and respondents from the general population were compared.”
> “After adjusting for baseline demographics and characteristics, NASH (N = 136) compared to the matched general population cohort (N = 544), reported significantly lower (worse) mental (MCS 43.19 vs. 46.22, p = 0.010) and physical (PCS 42.04 vs. 47.10, p < 0.001) status, higher % with anxiety (37.5% vs 25.5%, p = 0.006) and depression (43.4% vs 30.1%, p = 0.004)”
> “NASH cohort did not differ from matched T2DM cohort (N = 272) on mental or work-related WPAI scores, but had significantly worse physical status (PCS 40.52 vs. 44.58, p = 0.001), higher % with anxiety (39.9% vs 27.8%, p = 0.043)”

Source: [Tapper et al. (2023b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10077759/)

<a id="topic-2.2.1.8.1-2"></a>

### SF-36 physical and mental health by fibrosis stage in 713 adults with NAFLD, NASH Clinical Research Network

> “QOL data were collected from adults with NAFLD enrolled in the NASH Clinical Research Network using the SF-36 survey and scores were compared to normative U.S. population scores.”
> “A total of 713 subjects with NAFLD (M=269, F=444) were included. Mean age of subjects was 48.3 years; 61% had definite NASH, and 28% had bridging fibrosis or cirrhosis.”
> “Subjects with NAFLD had worse physical (mean=45.2) and mental health scores (mean=47.6) compared to the U.S. population with (mean=50) and without (physical: 55.8, mental: 52.5) chronic illness.”
> “Subjects with cirrhosis had significantly (P<0.001) poorer physical health scores (38.4) vs. subjects with no (47.6), mild (46.2), moderate (44.6) or bridging fibrosis (44.6).”
> “Mental health scores did not differ between participants with and without NASH or by degree of fibrosis.”

Source: [David et al. (2009)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2692572/)

<a id="topic-2.2.1.8.1-3"></a>

### Physical health-related patient-reported outcomes in 72 adults with biopsy-proven NASH and F2 or F3 fibrosis, as summarized in a systematic review

> “Biopsy-proven NASH with stage F2/F3 fibrosis (72)”
> “At baseline, physical health-related PROs of patients with NASH were lower than established general population levels, regardless of fibrosis stage (F3: p <0.05 for physical functioning, role-physical, general health, and PCS of SF-36; F2: p <0.05 for general health and PCS of SF-36)”
> “Health-related work productivity and activity impairment scores at baseline were significantly greater than 0 (p <0.05 except for absenteeism)”

Source: [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/)

<a id="topic-2.2.1.8.1-4"></a>

### Patient-reported outcomes in 1667 adults with NASH and F3 or F4 fibrosis versus the general population, STELLAR trial baseline

> “We analyzed data from 1667 patients (58 ± 9 years, 40% male, 52% with cirrhosis, 74% with diabetes) with NASH and bridging fibrosis or compensated cirrhosis (metavir scores, F3 or F4) enrolled in the phase 3 STELLAR trials of selonsertib (NCT03053050 and NCT03053063) who completed PRO questionnaires (SF-36, CLDQ-NASH, EQ-5D, or WPAI:SHP) before treatment initiation.”
> “Mean physical health-related PRO scores were significantly lower than those of the general population: patients with F4 fibrosis had score reductions of 4.4% to 12.9% in 6/8 SF-36 domains and patients with F3 fibrosis had score reductions of 3.9% to 11.7% in 4/8 domains (P < .01).”
> “In multivariate regression analysis, factors independently associated with lower PRO scores included having cirrhosis, female sex, higher body mass index, history of smoking, and diabetes or other comorbidities (P < .01).”

Source: [Younossi et al. (2019b)](https://pubmed.ncbi.nlm.nih.gov/30779990/)

<a id="topic-2.2.1.8.1-5"></a>

### Fatigue and pruritus in 1,669 adults with NASH and bridging fibrosis or compensated cirrhosis, STELLAR 3 and 4 baseline

> “were assessed at baseline in patients with histologically confirmed bridging fibrosis (F3) or compensated cirrhosis (F4) due to NASH enrolled in STELLAR 3 and 4.”
> “Among the included 1,669 patients with advanced NASH (mean age = 58 ± 9 years, 48% F3, 42% with psychiatric comorbidities), 33% and 27% had fatigue and pruritus, respectively.”
> “All PRO scores of patients with fatigue were significantly impaired (mean up to −31% of a PRO range size in comparison to patients without fatigue).”
> “All PROs were impaired (by up to −19% of a range size, all P < 0.01) in patients with NASH with pruritus.”
> “The median pruritus score was 6 (interquartile range [IQR] 4‐7) and did not differ between patients with bridging fibrosis and compensated cirrhosis (P = 0.55).”
> “Although patients with bridging fibrosis had higher median fatigue scores (indicative of less fatigue) than those with cirrhosis (5.0 [IQR 4.0‐5.8] vs. 4.7 [3.5‐5.7]; P = 0.0028), the difference does not meet the threshold of a minimal clinically important difference for domain scores of the CLDQ‐NASH (approximately 0.5 points).”

Source: [Younossi et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7603531/)

<a id="topic-2.2.1.8.1-6"></a>

### Patient-reported outcomes and fibrosis improvement in 392 adults with NASH and bridging fibrosis or compensated cirrhosis, phase 2 trial NCT03449446

> “Patients with NASH with bridging fibrosis or compensated cirrhosis were enrolled in a phase 2, randomized, placebo‐controlled study of selonsertib, firsocostat, or cilofexor, alone or in two‐drug combinations (NCT03449446).”
> “A total of 392 patients with NASH (mean ± SD, 60 ± 9 years old; 35% men; 89% white; 72% diabetes; and 56% compensated cirrhosis) were included.”
> “Baseline Physical Functioning (PF) and Bodily Pain of SF‐36 and Fatigue and Worry of CLDQ‐NASH were significantly lower in patients with cirrhosis (total CLDQ‐NASH score mean ± SD, 4.91 ± 1.06 with cirrhosis vs. 5.16 ± 1.14 without cirrhosis; P < 0.05).”
> “After 48 weeks of treatment, patients with ≥1‐stage fibrosis improvement without worsening of NASH experienced improvement in EQ‐5D and five out of six CLDQ‐NASH domains (P < 0.05).”
> “Fibrosis regression was independently associated with greater improvements in PF and EQ‐5D scores, while NAS improvement was associated with improvement in fatigue and pruritus (all P < 0.05).”

Source: [Younossi et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8279457/)

<a id="topic-2.2.1.8.1-7"></a>

### CLDQ-MASH domain scores by histologic fibrosis stage (F3 to F4 versus F0 to F2) in adults with MASH

> “There were 4,213 MASH patients included: age 56 ± 11 years, 44% male, 65% type 2 diabetes, 69% advanced fibrosis (F3–F4).”
> “After item reduction and exploratory factor analysis with the training set (>90% variance), the CLDQ-MASH contained 35 items and seven domains.”
> “Notably, in the context of liver disease severity, the CLDQ-MASH was able to discriminate individuals with vs. without histologic advanced fibrosis (p <0.05 for three domains and the total score)”

Source: [Younossi et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11835563/)

| CLDQ-MASH score (mean ± SD; 1 to 7, higher is better) | Histologic F3–F4 (n = 1,917) | Histologic F0–F2 (n = 868) | p value |
| --- | --- | --- | --- |
| Total CLDQ-MASH | “5.10 ± 1.14” | “5.19 ± 1.18” | “0.0281” |
| Activity | “5.33 ± 1.46” | “5.41 ± 1.55” | “0.0316” |
| Fatigue | “4.50 ± 1.46” | “4.55 ± 1.49” | “0.28” |
| Systemic symptoms | “4.91 ± 1.33” | “5.05 ± 1.33” | “0.0091” |
| Worry | “5.11 ± 1.53” | “5.31 ± 1.52” | “0.0002” |

Source: [Younossi et al. (2025b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11835563/)

<a id="topic-2.2.1.8.1-8"></a>

### CLDQ-NAFLD disease-specific instrument: 36 items in six domains

> “Thus, the resulting Chronic Liver Disease Questionnaire-Non-Alcoholic Fatty Liver Disease version instrument had 36 items grouped into six domains: Abdominal Symptoms, Activity, Emotional, Fatigue, Systemic Symptoms, and Worry.”
> “The domains' correlations with the most relevant domains of Short Form-36 exceeded 0.70.”

Source: [Younossi et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28211165/)

<a id="topic-2.2.1.8.1-9"></a>

### EQ-5D and CLDQ-NAFLD index by early (F0 to F2) and advanced (F3 to F4) fibrosis in adults with NASH, United States and five European countries, GAIN study

> “The Global Assessment of the Impact of NASH (GAIN) study is a prevalence-based burden of illness study across Europe (France, Germany, Italy, Spain, and the UK) and the USA.”
> “Of the patients, 767 (20%) provided information on indirect costs and health-related quality of life using the EuroQOL 5-D (EQ-5D; n = 749) and Chronic Liver Disease Questionnaire – Non-Alcoholic Fatty Liver Disease (CLDQ-NAFLD) (n = 723).”
> “All patients were categorised as having early (F0–F2) or advanced (F3–F4) fibrosis stage.”
> “In general, there was a clear pattern of decreasing HRQoL score with worsening fibrosis score in all countries, with the exception of France, where similar scores were seen in both early and advanced fibrosis.”
> “The average CLDQ-NAFLD index was 4.9, with France having the highest score at 5.7 and the USA having the lowest score of 4.4 (Table 3).”

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

| Index and population, mean (SD) | Early (F0–F2) | Advanced (F3–F4) | Overall |
| --- | --- | --- | --- |
| EQ-5D index, United States (n = 58, 36, 94) | “0.80 (0.19)” | “0.67 (0.23)” | “0.75 (0.22)” |
| EQ-5D index, all countries (n = 531, 218, 749) | “0.80 (0.2)” | “0.62 (0.33)” | “0.75 (0.26)” |
| CLDQ-NAFLD index, USA (n = 55, 36, 91) | “4.7 (1.05)” | “4.0 (1.12)” | “4.4 (1.12)” |
| CLDQ-NAFLD index, all countries (n = 513, 210, 723) | “5.2 (1.1)” | “4.4 (1.4)” | “4.9 (1.2)” |

Source: [O'Hara et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7397699/)

<a id="topic-2.2.1.8.1-10"></a>

### EQ-5D-5L by fibrosis stage and cardiovascular, renal, and metabolic comorbidity in adults with MASH, Canada, France, Germany, and Italy, 2024

> “Data were drawn from the Adelphi Real World MASH Disease Specific Programme™, a cross-sectional survey of physicians and patients with MASH in Canada, France, Germany, and Italy between January 2024 and June 2024.”
> “Patients were grouped as: early fibrosis (stage 0–2) without additional CVRM comorbidities (EFnoC); early fibrosis with additional CVRM comorbidities (EFwC); or advanced fibrosis (stage 3–4) with additional CVRM comorbidities (AFwC).”
> “Mean EQ-5D-5L scores were lower for EFwC patients (0.85 ± 0.16 [n = 524]) and AFwC patients (0.81 ± 0.18 [n = 113]) compared with EFnoC patients (0.90 ± 0.12 [n = 48], p <0.05 and p <0.001, respectively).”
> “Patients with AFwC experienced greater cognitive and emotional impairment, required professional caregivers more often, and had increased rates of hospitalization compared with those with EFwC.”

Source: [Marquardt et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13019595/)

<a id="topic-2.2.1.8.1-11"></a>

### Baseline mapped EQ-5D utility by fibrosis stage in 800 adults with biopsy-confirmed MASH and F2 or F3 fibrosis, ESSENCE trial part 1

> “Adults with biopsy-confirmed MASH and fibrosis stage F2 or F3 were randomized 2:1 to once-weekly subcutaneous semaglutide 2.4 mg or placebo plus standard of care.”
> “A total of 800 participants were included in this analysis (semaglutide 2.4 mg n = 534; placebo n = 266).”
> “31.3% of participants had stage 2 fibrosis, 68.8% had stage 3 fibrosis, and 55.9% had type 2 diabetes.”
> “Across the study population, the baseline mapped health utility (∼0.78, Table 1) was lower than that reported in the literature for a similar patient population (0.84).”

Source: [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

| Baseline group | Baseline EQ-5D utility, mean (SD) |
| --- | --- |
| Fibrosis stage 2, semaglutide (n = 169) | “0.783 (0.186)” |
| Fibrosis stage 2, placebo (n = 81) | “0.789 (0.190)” |
| Fibrosis stage 3, semaglutide (n = 365) | “0.792 (0.176)” |
| Fibrosis stage 3, placebo (n = 185) | “0.769 (0.194)” |

Source: [Augusto et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13651485/)

<a id="topic-2.2.1.8.1-12"></a>

### Pruritus, fatigue, and sleep disorders in 8034 adults with MASLD, Global NAFLD/MASLD Registry

> “Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry.”
> “A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms.”
> “All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss.”

Source: [Younossi et al. (2026c)](https://pubmed.ncbi.nlm.nih.gov/42925568/)

<a id="topic-2.2.1.8.1-13"></a>

### SF-6D health utility in noncirrhotic and cirrhotic NAFLD, 89 outpatients

> “There were 89 patients with the spectrum of NAFLD completed the SF-36 questionnaire: 59 with non-cirrhotic NAFLD and 30 with cirrhosis.”
> “Patients with NAFLD had significantly lower quality of life and health utility scores than the general population (all p<0.0001).”
> “Furthermore, patients with cirrhosis had lower quality of life and utility scores than non-cirrhotic NAFLD patients: SF-6D 0.660±0.107 in non-cirrhotic NAFLD vs 0.551±0.138 in cirrhotic NAFLD (p=0.0003).”

Source: [Sayiner et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5013331/)

<a id="topic-2.2.1.8.1-14"></a>

### Health-related quality of life in NASH: systematic review of 23 studies

> “Twenty-five publications covering 23 unique studies were identified. Overall, the data showed a substantial impact of NASH on HRQoL, particularly in terms of physical functioning and fatigue, with deterioration of physical and mental health as NASH progresses.”
> “Prevalent symptoms, including fatigue, abdominal pain, anxiety/depression, cognition problems, and poor sleep quality, adversely impact patients’ ability to work and perform activities of daily living and the quality of relationships.”
> “Most studies were rated ‘moderate’ at quality assessment, and all evaluable studies had inadequate control of confounders.”

Source: [Younossi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9418497/)

<a id="topic-2.2.1.8.1-15"></a>

### Fibrosis stage and quality of life: meta-analysis of 13 cohort studies

> “Our meta-analysis included 13 studies, comprising 4428 patients with NAFLD; 2875 of these were reported to have NASH.”
> “Three studies examined the effects of increasing fibrosis on quality of life had inconsistent findings.”
> “Further studies are needed to assess the association between fibrosis stage and patient quality of life and establish that change in liver fibrosis stage is a valid endpoint for use in clinical trials.”

Source: [Taylor et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32027911/)

## Related pages
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Terms and abbreviations](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/terms-and-abbreviations.md)
- [Lanifibranor (IVA337): Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/executive-summary.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Product information and disease description](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/product-information-and-disease-description.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Clinical evidence](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/clinical-evidence.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: Economic information and modeling report](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/economics.md)
- [Lanifibranor (IVA337) in Metabolic dysfunction-associated steatohepatitis with F2 to F3 fibrosis: References](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references) · [Markdown](https://www.evicenter.com/drugs/lanifibranor--metabolic-dysfunction-associated-steatohepatitis-with-f2-to-f3-fibrosis/references.md)
